ATF3 and nasopharyngeal carcinoma: rs41545520G creates a binding site for the transcriptional repressor, ATF3, leading to reduced HLA expression in nasopharyngeal carcinomas and consequently resulting in reduced presentation of tumour-associated antigens to CD8+ T lymphocytes and increased immune evasion (31).